Peter Joseph Pappas Fund established to accelerate the Foundation's research goals
The Preeclampsia Foundation is pleased to announce the establishment of the Peter Joseph Pappas Fund, a restricted fund with the primary goal of supporting research that will end pre-term deliveries due to preeclampsia and related disorders of pregnancy by 2050.
Established by Clement and Lauren Pappas of Philadelphia, PA, in honor of their son, Peter Joseph, the fund will help support new and innovative approaches to researching this age-old disease that still has no cure. Peter Joseph died after being born prematurely due to severe HELLP syndrome experienced by Lauren at 28 weeks.
Clement and Lauren have set their goal for $1 million in donations from family and friends over the next five years. Generous donations to date have already surpassed $135,000 and pledges have reached $835,000.
The Preeclampsia Foundation's mission is to reduce maternal and infant illness and death due to preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy. As the only nonprofit in the U.S. dedicated to these diseases, the Preeclampsia Foundation is dedicated to keeping families whole.
Related Articles
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
1777566412.png)
Placental dysfunction can result in conditions such as preeclampsia, which have traditionally been managed with close monitoring and appropriately timed delivery. There is currently no cure for preecl...
1777563523.png)
Gestational hypertension continues to be a growing public health concern contributing to maternal morbidity, mortality, and long-term health complications in the U.S. While changes in vision—suc...
1777562643.png)
Background Low-dose aspirin (81 mg) is a treatment known to help lower the risk of preeclampsia. However, not everyone who is at higher risk is told to take it. This study looks at whether a screening...
Women who experienced Preeclampsia have a higher lifetime risk of developing cardiovascular disease (CVD) than women who did not suffer from this pregnancy complication. Researchers wanted to know if...
Preeclampsia Foundation and Preeclampsia Foundation Canada announced that applications are now being accepted for the 2026 Vision Grant research funding program. Three of the four grants focus on heal...